Home > > > News

Label Change Approved for Vyvanse

Once-daily drug now may cover symptoms for up to 13 hours.

Friday June 5th - 3:30pm

Biopharmaceutical company Shire has received FDA approval to change the prescribing information for its once-daily attention deficit hyperactivity disorder (ADHD) treatment Vyvanse, for up to 13 hours.

Studies on the medication in children ages 6 to 12 have shown symptom control from 1.5 hours (the first time point measured) through 13 hours postdose. The most frequently reported adverse events were decreased appetite, insomnia, headache, irritability, upper abdominal pain, and mood swings.

Vyvanse has been approved for the treatment of ADHD in children aged 6 to 12 years and adults. It is currently available in six dosage strengths.

Read more about the new labeling.

What do you think of this article? Share your comments on www.ADDConnect.com, ADDitude's community site. Check out the new ADHD Medication User Reviews and the ADHD Adults Support Group. Your fellow ADDers want to hear from you!

Copyright © 1998 - 2013 New Hope Media LLC. All rights reserved. Your use of this site is governed by our Terms of Service and Privacy Policy.
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only. See additional information.
New Hope Media, 39 W. 37th Street, 15th Floor, New York, NY 10018